Search - tctmd.com

Displaying 101 - 120 of 453

Sort: Relevancy | Date

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

News Daily News

New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

Yael L. Maxwell

May 08, 2024

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

News Daily News

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Michael O'Riordan

May 07, 2024

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

News Daily News

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Michael O'Riordan

May 06, 2024

TCTMD’s Top 10 Most Popular Stories for April 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2024

April 30, 2024

New Heart Failure After AF Diagnosis Merits More Attention

News Daily News

New Heart Failure After AF Diagnosis Merits More Attention

April 18, 2024

Should Conduction-System Pacing Be Top Choice for CRT?

News Conference News EHRA 2024

Should Conduction-System Pacing Be Top Choice for CRT?

April 15, 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

News Conference News ACC 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

April 15, 2024

Ultralow-Temperature Cryoablation Promising for Monomorphic VT

News Conference News EHRA 2024

Ultralow-Temperature Cryoablation Promising for Monomorphic VT

April 12, 2024

Efficacy and Safety of Ninerafaxstat, a Novel Cardiac Mitotrope, in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (Results of IMPROVE-HCM)

Presentation ACC 2024

Efficacy and Safety of Ninerafaxstat, a Novel Cardiac Mitotrope, in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (Results of IMPROVE-HCM)

Presenter: Martin S. Maron

April 08, 2024

A Selective Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiomyopathy

Presentation ACC 2024

A Selective Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiomyopathy

Presenter: James L. Januzzi Jr

April 08, 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

April 06, 2024

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

News Conference News ACC 2024

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

Michael O'Riordan

April 06, 2024

ADHD Meds Linked to Cardiomyopathy in Young Adults

News Conference News ACC 2024

ADHD Meds Linked to Cardiomyopathy in Young Adults

April 01, 2024

Evoque and Patisiran: A Tale of Two Regulatory Journeys

News Opinion Off Script

Evoque and Patisiran: A Tale of Two Regulatory Journeys

Sanjay Kaul, MD

March 29, 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

US Sees a Surge in Cardiomyopathy-Linked Hospital Stays Among Meth Users

News Daily News

US Sees a Surge in Cardiomyopathy-Linked Hospital Stays Among Meth Users

March 18, 2024

Smart Scale Better at Predicting HF Events Than Weight-Based Monitoring

News Conference News THT 2024

Smart Scale Better at Predicting HF Events Than Weight-Based Monitoring

Michael O'Riordan

March 11, 2024

Small Study Hints at Potential for HF Bone Marrow Cell Therapy: CardiAMP-HF

News Conference News THT 2024

Small Study Hints at Potential for HF Bone Marrow Cell Therapy: CardiAMP-HF

Michael O'Riordan

March 08, 2024

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

News Conference News THT 2024

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

Michael O'Riordan

March 06, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.